Bengaluru, India – Pandorum Technologies, a biotechnology startup specializing in programmable regenerative medicine, has successfully raised $18 million in a Series B funding round to advance the clinical development of its disease-modifying, tunable, exosome-based therapies, including its lead ophthalmology program, Kuragenx. The capital will also support scaling of global manufacturing operations and expansion into the United States, Japan, and the Middle East. The funding round was led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, the Burman Family, and other backers. Bandana Kankani, advisor and investor at Pandorum, guided the transaction and worked to align the investment structure with the company’s long-term value creation strategy.
Founded by Tuhin Bhowmick and Arun Chandru, Pandorum Technologies operates across India and the United States. The company leverages a proprietary platform that integrates biology, engineering, and computational methods to develop tunable regenerative exosome therapies capable of reprogramming pathological tissue states, such as inflammation and fibrosis, toward functional recovery. “Just like the Ship of Theseus, the human body is constantly being rebuilt. Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core,” said Tuhin Bhowmick, co-founder and CEO.
He added, “Our approach treats tissue health, disease, and degeneration as a navigational challenge within an information-constrained biological landscape. This funding will enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair, aligned with Pandorum’s vision to heal fast and age slow.” Pandorum has adopted a globally distributed manufacturing approach. The company has partnered with AGC Biologics in Italy to support manufacturing for the US and European markets and is collaborating with Nucelion Therapeutics, a subsidiary of Bharat Biotech, to facilitate supply across the Asia-Pacific region. The startup is also exploring potential partnerships in the Middle East to strengthen regional access and distribution.
Clinical translation efforts are being guided by leading clinicians including Dr. Virender Singh Sangwan of Dr. Shroff’s Charity Eye Hospital in New Delhi, Dr. Shigeru Kinoshita of Kyoto Prefectural University of Medicine, and Drs. Ramez Haddadin and Satish Nadig of Northwestern Medicine in Chicago. According to startup data platform TheKredible, Pandorum has raised approximately $43 million to date, including an $11 million extension of its Series A funding secured last year.
The company’s primary clinical focus is on ocular surface diseases such as Stevens–Johnson Syndrome and Neurotrophic Keratitis. Its lead ophthalmology program, Kuragenx, has received Orphan Drug Designation from the US Food and Drug Administration. Beyond ophthalmology, Pandorum is expanding its platform to develop regenerative therapies for inflammatory and degenerative conditions affecting organs including the lungs, liver, and nervous system.
